The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The primary biliary cholangitis (PBC) market has seen substantial growth recently, with the market size increasing from $0.87 billion in 2023 to $0.98 billion in 2024, reflecting a compound annual growth rate (CAGR) of 12.1%.

Key Drivers of Historical Growth:

• Increased Disease Awareness: Greater knowledge about PBC has led to early diagnosis and treatment.
• Rising Global Healthcare Expenditure: Higher spending on healthcare supports the development and adoption of new treatments.
• Strategic Collaborations: Partnerships in the healthcare sector foster innovation and access to treatments.
• Focus on Patient Advocacy: Efforts to support and educate patients have improved care.
• Government Initiatives: Programs aimed at improving liver health have bolstered the market.

Projected Market Expansion

The PBC market is expected to continue its rapid growth, reaching $1.46 billion by 2028, with a CAGR of 10.4%.

Future Growth Drivers:

• Expansion of Biomarker Research: Improved diagnostics and personalized treatment options.
• Global Efforts in Rare Disease Management: International collaboration to manage and treat rare diseases like PBC.
• Increased Collaboration in Clinical Trials: More joint efforts in research and development.
• Patient-centric healthcare Approaches: Treatments focused on individual patient needs.
• Rising Demand for Liver Transplants: More patients seeking transplants due to advanced disease.

View More On The Primary Biliary Cholangitis Market Report 2024 – https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Major Trends Shaping the Market:

• Advancements in Biomarker Research: Enhancing early diagnosis and personalized medicine.
• Non-Invasive Diagnostic Techniques: Reducing the need for invasive procedures.
• Immunomodulatory Therapies: Developing treatments that modify the immune response.
• Artificial Intelligence Integration: Utilizing AI for better diagnostics and treatment plans.
• Patient-reported outcomes in Clinical Trials: Including patient feedback to improve treatment efficacy.
• Telemedicine for Patient Management: Offering remote consultations and follow-ups.
• Combination Therapies: Using multiple drugs for more effective treatment.
• Emerging Therapies Targeting Fibrosis: Addressing liver scarring associated with PBC.

Impact of Rising Smoking Rates

The increase in smoking rates is expected to drive market growth for PBC treatments. Smoking is a known risk factor for liver diseases, including PBC.

Example:

• Statistics Canada Report (July 2023):
  • Cigarette Production: Increased by 2.2% compared to June 2023.
  • Cigarette Sales: Rose by 2.6% in June, reaching 1.4 billion units.

Leading Companies and Innovations

Several major companies are leading the PBC market with innovative treatments and strategic acquisitions.

Key Players:

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck And Co. Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC

Innovative Treatments:

• Orphan Drug Combinations: Combining obeticholic acid (OCA) and bezafibrates for enhanced treatment.
  • Example: In May 2023, Intercept Pharmaceuticals received FDA orphan drug designation for the combination of OCA and bezafibrate.

Strategic Acquisitions

Ipsen’s Acquisition of Albireo Pharma:

• Date: March 2023
• Objective: Expand focus on rare cholestatic liver illnesses.
• Outcome: Strengthened portfolio with novel pipeline prospects and promising therapies for PBC.

Market Segmentation

The PBC market is segmented based on treatment type, diagnosis, and end-user.

By Treatment Type:

• Drugs, Liver Transplantation

By Diagnosis:

• Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

By End-User:

• Specialty Clinics, Homecare, Other End-Users

Regional Insights

In 2023, North America was the largest region in the PBC market, while the Asia-Pacific region is expected to be the fastest-growing in the forecast period.

Conclusion

The primary biliary cholangitis market is experiencing rapid growth, driven by increased awareness, technological advancements, and strategic collaborations. As research and development continue to evolve, the market is set to expand further, offering improved treatments and better patient outcomes.

Request A Sample Of The Global Primary Biliary Cholangitis Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13520&type=smp